Kadmon Holdings (Kadmon Holdings) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2021)

View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings ROE % Adjusted to Book Value?

Kadmon Holdings's ROE % for the quarter that ended in Sep. 2021 was -573.69%. Kadmon Holdings's PB Ratio for the quarter that ended in Sep. 2021 was N/A. Kadmon Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2021 was N/A.

Kadmon Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Kadmon Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings ROE % Adjusted to Book Value Chart

Kadmon Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-23.59

-8.23

-7.77

Kadmon Holdings Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-9.38	-8.70	-2.73	-	-

Competitive Comparison of Kadmon Holdings's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Kadmon Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kadmon Holdings's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadmon Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kadmon Holdings's ROE % Adjusted to Book Value falls into.

Kadmon Holdings ROE % Adjusted to Book Value Calculation

Kadmon Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2020 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-77.31%	/	9.95
	=	-7.77%

Kadmon Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2021 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-573.69%	/	N/A
	=	N/A

Kadmon Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadmon Holdings (Kadmon Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East 29th Street, New York, NY, USA, 10016

Website

https://www.kadmon.com

Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.

Executives

Harlan Waksal	director, officer: President, CEO	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer	director	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris	director	103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan	officer: Executive Vice President, CMO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan	officer: EVP, Chief Financial Officer	450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver	officer: Principal Accounting Officer, Controller	450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss	officer: EVP, General Counsel, Chief Compliance Officer	450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	other: Former 10% owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon	officer: Exec VP, GC, Chief Admin, Comp	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016